Cochrane Briefs


Am Fam Physician. 2004 Oct 1;70(7):1269-1270.

Drug Treatments for Patients with Dysthymia

Clinical Question

Which drug treatments for dysthymia are most effective?

Evidence-Based Answer

All antidepressants studied have similar efficacy in the treatment of patients with dysthymia. Side effect profiles vary. The largest comparisons support the use of tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs).

Practice Pointers

Patients with dysthymia have less severe but more chronic symptoms than patients with depression. De Lima and colleagues published two systematic reviews1,2 on the treatment of dysthymia. The first review, by De Lima and Moncrieff,1 found that antidepressants are highly effective in treating dysthymia compared with placebo. Approximately four patients must be treated to achieve one response. However, it is not clear which antidepressant produces the best results.

To determine the most effective antidepressant, De Lima and Hotopf2 searched for randomized and quasi-randomized controlled trials comparing at least two active drug treatments. Patients in these studies had dysthymia for at least two years and were studied for four to 12 weeks in psychiatric, primary care, and community settings.

Tricyclic antidepressants, SSRIs and monoamine oxidase inhibitors had similar efficacy. Imipramine was the most commonly studied tricyclic antidepressant, and fluoxetine was the most commonly studied SSRI. Only one study compared SSRIs with tricyclic antidepressants. Both drug classes had a similar effect on mood, but the SSRIs had a lower dropout rate. Therefore, medication choice should be based on the side effect profile. No data are available on optimal dosage or length of treatment.


1. De Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev. 2000;4:CD001130.

2. De Lima MS, Hotopf M. A comparison of active drugs for the treatment of dysthymia. Cochrane Database Syst Rev. 2003;3:CD00404.



Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article